Comparison of survival of patients with metastases from known versus unknown primaries: Survival in metastatic cancer

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Riihimäki, Matias ^a,b   Thomsen, Hauke ^a   Hemminki, Akseli ^c   Sundquist, Kristina ^b,d   Hemminki, Kari ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF HELSINKI   (Finland)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer of unknown primary; Cancer survival; CUP; Metastasis; Regression analysis

Indexed keywords

ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER OF KNOWN PRIMARY SITE; CANCER OF UNKNOWN PRIMARY SITE; CANCER PATIENT; CANCER REGISTRY; CANCER SURVIVAL; CONTROLLED STUDY; HAZARD RATIO; HUMAN; IMMUNE DEFICIENCY; LIVER CANCER; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; MUTATION; PANCREAS CANCER; PATIENT IDENTIFICATION; PROGNOSIS; STOMACH CANCER; SURVIVAL TIME; SWEDEN;

BONE NEOPLASMS; BRAIN NEOPLASMS; DIGESTIVE SYSTEM NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; NEOPLASMS, UNKNOWN PRIMARY; PROGNOSIS; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SWEDEN; TIME FACTORS;

EID: 84872781432     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-36     Document Type: Article

References (40)

1. Langley RR, Fidler IJ. The seed and soil hypothesis revisited-the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer 2011, 128(11):2527-2535. 10.1002/ijc.26031, 3075088, 21365651.
2. Sleeman JP, Nazarenko I, Thiele W. Do all roads lead to Rome? Routes to metastasis development. Int J Cancer 2011, 128(11):2511-2526. 10.1002/ijc.26027, 21365648.
3. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006, 12(8):895-904. 10.1038/nm1469, 16892035.
4. Klein CA. Parallel progression of primary tumours and metastases. Nat Rev Cancer 2009, 9(4):302-312. 10.1038/nrc2627, 19308069.
5. Collado M, Serrano M. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer 2010, 10(1):51-57. 10.1038/nrc2772, 20029423.
6. Nguyen DX, Massague J. Genetic determinants of cancer metastasis. Nat Rev Genet 2007, 8(5):341-352.
7. Chen LL, Blumm N, Christakis NA, Barabasi AL, Deisboeck TS. Cancer metastasis networks and the prediction of progression patterns. Br J Cancer 2009, 101(5):749-758. 10.1038/sj.bjc.6605214, 2736851, 19707203.
8. Smedby KE, Brandt L, Backlund ML, Blomqvist P. Brain metastases admissions in Sweden between 1987 and 2006. Br J Cancer 2009, 101(11):1919-1924. 10.1038/sj.bjc.6605373, 2788258, 19826419.
9. Disibio G, French SW. Metastatic patterns of cancers: results from a large autopsy study. Arch Pathol Lab Med 2008, 132(6):931-939.
10. Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL. Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res 1999, 5(11):3403-3410.
11. Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, Abbruzzese JL. Metastatic patterns in adenocarcinoma. Cancer 2006, 106(7):1624-1633. 10.1002/cncr.21778, 16518827.
12. Johansson LA, Westerling R. Comparing Swedish hospital discharge records with death certificates: implications for mortality statistics. Int J Epidemiol 2000, 29(3):495-502. 10.1093/ije/29.3.495, 10869322.
13. Cohen J, Bilsen J, Addington-Hall J, Lofmark R, Miccinesi G, Kaasa S, Onwuteaka-Philipsen B, Deliens L. Population-based study of dying in hospital in six European countries. Palliat Med 2008, 22(6):702-710. 10.1177/0269216308092285, 18715968.
14. Dödsorsaker 2010 (Causes of death 2010) The Swedish national board of health and welfare Accessible online at http://www.socialstyrelsen.se/publikationer2011/2011-7-6, Dödsorsaker 2010 (Causes of death 2010).
15. van de Wouw AJ, Jansen RL, Speel EJ, Hillen HF. The unknown biology of the unknown primary tumour: a literature review. Ann Oncol 2003, 14(2):191-196. 10.1093/annonc/mdg068, 12562643.
16. Bartelt S, Lutterbach J. Brain metastases in patients with cancer of unknown primary. J Neurooncol 2003, 64(3):249-253. 10.1023/A:1025621819250, 14558600.
17. Hemminki K, Ji J, Brandt A, Mousavi SM, Sundquist J. The Swedish family-cancer database 2009: prospects for histology-specific and immigrant studies. Int J Cancer 2010, 126(10):2259-2267.
18. Hemminki K, Bevier M, Sundquist J, Hemminki A. Cancer of unknown primary (CUP): does cause of death and family history implicate hidden phenotypically changed primaries?. Ann Oncol 2012, 23:2720-2724. 10.1093/annonc/mds063, 22473595.
19. Lazaridis G, Pentheroudakis G, Fountzilas G, Pavlidis N. Liver metastases from cancer of unknown primary (CUPL): a retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature. Cancer Treat Rev 2008, 34(8):693-700. 10.1016/j.ctrv.2008.05.005, 18584969.
20. Karavasilis V, Malamou-Mitsi V, Briasoulis E, Tsanou E, Kitsou E, Kalofonos H, Fountzilas G, Fotsis T, Pavlidis N. Matrix metalloproteinases in carcinoma of unknown primary. Cancer 2005, 104(10):2282-2287. 10.1002/cncr.21454, 16220559.
21. Karavasilis V, Malamou-Mitsi V, Briasoulis E, Tsanou E, Kitsou E, Kalofonos H, Fountzilas G, Fotsis T, Pavlidis N. Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1. BMC Cancer 2005, 5(1):25. 10.1186/1471-2407-5-25, 555600, 15743540.
22. Hemminki K, Bevier M, Hemminki A, Sundquist J. Survival in cancer of unknown primary site: population-based analysis by site and histology. Ann Oncol 2012, 23(7):1854-1863. 10.1093/annonc/mdr536, 22115926.
23. Pavlidis N, Pentheroudakis G. Cancer of unknown primary site. Lancet 2012, 379:1428-1435. 10.1016/S0140-6736(11)61178-1, 22414598.
24. Randen M, Rutqvist LE, Johansson H. Cancer patients without a known primary: incidence and survival trends in Sweden 1960-2007. Acta Oncol 2009, 48:915-920. 10.1080/02841860902862503, 19363713.
25. Shu X, Sundquist K, Sundquist J, Hemminki K. Time trends in incidence, causes of death, and survival of cancer of unknown primary in Sweden. Eur J Cancer Prev 2012, 21:281-288. 10.1097/CEJ.0b013e32834c9ceb, 21968687.
26. Fizazi K, Greco FA, Pavlidis N, Pentheroudakis G. Cancer of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011, 22(Suppl 6):vi64-vi68.
27. Greco FA, Oien K, Erlander M, Osborne R, Varadhachary G, Bridgewater J, Cohen D, Wasan H. Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes. Ann Oncol 2012, 23:298-304. 10.1093/annonc/mdr306, 21709138.
28. Mylona S, Stroumpouli E, Pomoni M, Galani P, Ntai S, Thanos L. Radiofrequency ablation of liver metastases from cancer of unknown primary site. Diagn Interv Radiol 2009, 15(4):297-302.
29. Van Cutsem E, Nordlinger B, Adam R, Kohne CH, Pozzo C, Poston G, Ychou M, Rougier P. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006, 42(14):2212-2221. 10.1016/j.ejca.2006.04.012, 16904315.
30. Morris EJ, Forman D, Thomas JD, Quirke P, Taylor EF, Fairley L, Cottier B, Poston G. Surgical management and outcomes of colorectal cancer liver metastases. Br J Surg 2010, 97(7):1110-1118. 10.1002/bjs.7032, 20632280.
31. DeWitt J, Yu M, Al-Haddad MA, Sherman S, McHenry L, LeBlanc JK. Survival in patients with pancreatic cancer after the diagnosis of malignant ascites or liver metastases by EUS-FNA. Gastrointest Endosc 2010, 71(2):260-265. 10.1016/j.gie.2009.08.025, 19922924.
32. Shrikhande SV, Kleeff J, Reiser C, Weitz J, Hinz U, Esposito I, Schmidt J, Friess H, Buchler MW. Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann Surg Oncol 2007, 14(1):118-127.
33. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011, 364(19):1817-1825. 10.1056/NEJMoa1011923, 21561347.
34. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006, 12(20 Pt 2):6243s-6249s.
35. Weiss RJ, Wedin R. Surgery for skeletal metastases in lung cancer. Acta Orthop 2011, 82(1):96-101. 10.3109/17453674.2011.552779, 3230004, 21281260.
36. Chan T, Wiltrout RH, Weiss JM. Immunotherapeutic modulation of the suppressive liver and tumor microenvironments. Int Immunopharmacol 2011, 11(7):879-889. 10.1016/j.intimp.2010.12.024, 3082592, 21241810.
37. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002, 3(11):991-998. 10.1038/ni1102-991, 12407406.
38. Pavlidis N, Briasoulis E, Pentheroudakis G. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl 5):v228-v231.
39. Piga A, Nortilli R, Cetto GL, Cardarelli N, Fedeli SL, Fiorentini G, D'Aprile M, Giorgi F, Parziale AP, Contu A, et al. Carboplatin, doxorubicin and etoposide in the treatment of tumours of unknown primary site. Br J Cancer 2004, 90(10):1898-1904. 10.1038/sj.bjc.6601785, 2409455, 15138469.
40. van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW, Hillen HF. Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992. Eur J Cancer 2002, 38(3):409-413. 10.1016/S0959-8049(01)00378-1, 11818207.